These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 10919407)

  • 21. Neutralizing antiidiotypic antibodies to factor VIII inhibitors after desensitization in patients with hemophilia A.
    Gilles JG; Desqueper B; Lenk H; Vermylen J; Saint-Remy JM
    J Clin Invest; 1996 Mar; 97(6):1382-8. PubMed ID: 8617869
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anti-idiotypes to factor VIII antibodies and their possible role in the pathogenesis and treatment of factor VIII inhibitors.
    Moffat EH; Furlong RA; Dannatt AH; Bloom AL; Peake IR
    Br J Haematol; 1989 Jan; 71(1):85-90. PubMed ID: 2492821
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characterization of human hybridoma clones isolated from hemophilia patients with specificity for different domains of coagulating factor VIII.
    Gharagozlou S; Ghods R; Bahrami ZS; Roohi A; Jeddi-Tehrani M; Conti-Fine BM; Sharifian RA; Rabbani H; Shokri F
    Hum Antibodies; 2003; 12(3):67-76. PubMed ID: 14646035
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cross-reactive idiotypes on high affinity IgG class human monoclonal thyroglobulin autoantibodies.
    Delves PJ; McLachlan SM; Drewe E; Fukuma N; Petersen VB; Smith BR
    J Autoimmun; 1993 Feb; 6(1):77-91. PubMed ID: 8457287
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Induction of human factor VIII inhibitors in rats by immunization with human recombinant factor VIII: a small animal model for humans with high responder inhibitor phenotype.
    Jarvis MA; Levin LG; Harrison JA; DePianto DJ; Suzuki CM; Ziaja CL; Brown JE; Jolly KW; Reisner HM; Abildgaard CF; Powell JS
    Thromb Haemost; 1996 Feb; 75(2):318-25. PubMed ID: 8815584
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Does peroral administration of factor VIII induce oral tolerance in patients with acquired haemophilia A?
    Lindgren A; Wadenvik H; Tarkowski A; Tengborn L
    Thromb Haemost; 2000 Apr; 83(4):632-3. PubMed ID: 10780332
    [No Abstract]   [Full Text] [Related]  

  • 27. Immunochemical characterization of factor VIII inhibitors.
    Hoyer LW; Gawryl MS; de la Fuente B
    Prog Clin Biol Res; 1984; 150():73-85. PubMed ID: 6431443
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Induction of factor VIII-specific unresponsiveness by intrathymic factor VIII injection in murine hemophilia A.
    Madoiwa S; Yamauchi T; Kobayashi E; Hakamata Y; Dokai M; Makino N; Kashiwakura Y; Ishiwata A; Ohmori T; Mimuro J; Sakata Y
    J Thromb Haemost; 2009 May; 7(5):811-24. PubMed ID: 19220731
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Human monoclonal multiple-organ-reactive autoantibodies distinguished by mouse monoclonal anti-idiotypic antibodies: expression of idiotopes in humans with and without autoimmune diseases.
    Uchigata Y; Prabhakar BS; Salata KF; Ginsberg-Fellner F; Notkins AL
    J Immunol; 1987 Jun; 138(12):4218-21. PubMed ID: 3495582
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anti-idiotypic immunity and autoimmunity. I. In vitro and in vivo effects of anti-idiotypic antibodies to spontaneously occurring autoantibodies to rat thyroglobulin.
    Zanetti M; Bigazzi PE
    Eur J Immunol; 1981 Mar; 11(3):187-95. PubMed ID: 6972305
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibitor antibodies to factor VIII and factor IX: management.
    Lusher JM
    Semin Thromb Hemost; 2000; 26(2):179-88. PubMed ID: 10919411
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Porcine factor VIII].
    De Juan MJ; Montoro JB; Tusell JM
    Sangre (Barc); 1991 Jun; 36(3):217-20. PubMed ID: 1948542
    [No Abstract]   [Full Text] [Related]  

  • 33. Studies on the neutralization of rabbit antibodies to human factor VIII.
    Kernoff PB; Kaelin AC
    Thromb Haemost; 1977 Oct; 38(3):707-16. PubMed ID: 74103
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Comparison of anti-human and anti-porcine factor VIII antibody titers in patients with hemophilia].
    Windyga J; Rzymkiewicz L; Lopaciuk S
    Acta Haematol Pol; 1996; 27(1):27-31. PubMed ID: 8629440
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The suppression of factor VIII antibodies in haemophilia.
    Dormandy KM; Sultan Y
    Pathol Biol (Paris); 1975 Dec; 23 suppl():17-23. PubMed ID: 772555
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anti-idiotypic suppression of autoantibodies with high dose intravenous immunoglobulins.
    Kazatchkine MD
    Prog Clin Biol Res; 1990; 337():411-4. PubMed ID: 2112754
    [No Abstract]   [Full Text] [Related]  

  • 37. Hemophilia factor VIII therapy. Immunological tolerance. A clinical perspective.
    White GC; Greenwood R; Escobar M; Frelinger JA
    Haematologica; 2000 Oct; 85(10 Suppl):113-6. PubMed ID: 11187862
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Healthy subjects produce both anti-factor VIII and specific anti-idiotypic antibodies.
    Gilles JG; Saint-Remy JM
    J Clin Invest; 1994 Oct; 94(4):1496-505. PubMed ID: 7523452
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hemophilia. Strategies for the treatment of inhibitor patients.
    Ingerslev J
    Haematologica; 2000 Oct; 85(10 Suppl):15-20. PubMed ID: 11187863
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The humoral immune response in autoimmunity.
    Calvanico NJ
    Dermatol Clin; 1993 Jul; 11(3):379-89. PubMed ID: 8365026
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.